| |||||
| |||||
|
Monday, October 31, 2011
Recalled Chicken Pot Pie Empanadas Contain Plastic
Thursday, October 27, 2011
Turkish Pine Nuts Recalled due to Salmonella
Wegmans Food Markets, Inc. Announces Recall of Bulk Turkish Pine
Nuts Due to Possible Salmonella Contamination
FOR IMMEDIATE RELEASE - October 26, 2011 - Rochester, NY - Wegmans Food Markets, Inc. is recalling approximately 5,000 lbs. of Turkish Pine Nuts sold in the Bulk Foods department of most Wegmans stores in New York, Pennsylvania, New Jersey, Virginia, and Maryland between July 1 and October 18, 2011 due to possible Salmonella contamination.
The bulk Turkish Pine Nuts have been linked to an outbreak of illness from Salmonella Enteritidis, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. Illness onset is typically 12 to 72 hours after consumption.
This recall only applies to Turkish Pine Nuts sold in bulk. Other pine nuts sold at Wegmans are not affected by this recall.
The recalled Turkish pine nuts were imported from Turkey by Sunrise Commodities of Englewood Cliffs, N.J.
The recalled product was not sold at the company’s Northborough, Massachusetts store, which opened on Sunday, October 16.
The recall was initiated as a result of a multi-state outbreak investigation by the Centers for Disease Control and Prevention (CDC) (www.cdc.gov/salmonella). Wegmans is working closely with the CDC, the Food and Drug Administration (FDA), and state and local public health and agriculture officials on this matter.
Wegmans has placed automated phone calls to customers who purchased the Turkish Pine Nuts using their Shoppers Club card alerting them about the recall.
Consumers who have purchased this product should discard any that remains in their homes and visit the service desk at Wegmans for a full refund. Consumers with questions may contact Wegmans consumer affairs department toll free at 1(800) WEGMANS (934-6267) Monday through Friday, between 8:00 a.m. and 5:00 p.m. Eastern time.
Wegmans Food Markets, Inc. is a 79-store supermarket chain with stores in New York, Pennsylvania, New Jersey, Virginia, Maryland, and Massachusetts.
The bulk Turkish Pine Nuts have been linked to an outbreak of illness from Salmonella Enteritidis, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. Illness onset is typically 12 to 72 hours after consumption.
This recall only applies to Turkish Pine Nuts sold in bulk. Other pine nuts sold at Wegmans are not affected by this recall.
The recalled Turkish pine nuts were imported from Turkey by Sunrise Commodities of Englewood Cliffs, N.J.
The recalled product was not sold at the company’s Northborough, Massachusetts store, which opened on Sunday, October 16.
The recall was initiated as a result of a multi-state outbreak investigation by the Centers for Disease Control and Prevention (CDC) (www.cdc.gov/salmonella). Wegmans is working closely with the CDC, the Food and Drug Administration (FDA), and state and local public health and agriculture officials on this matter.
Wegmans has placed automated phone calls to customers who purchased the Turkish Pine Nuts using their Shoppers Club card alerting them about the recall.
Consumers who have purchased this product should discard any that remains in their homes and visit the service desk at Wegmans for a full refund. Consumers with questions may contact Wegmans consumer affairs department toll free at 1(800) WEGMANS (934-6267) Monday through Friday, between 8:00 a.m. and 5:00 p.m. Eastern time.
Wegmans Food Markets, Inc. is a 79-store supermarket chain with stores in New York, Pennsylvania, New Jersey, Virginia, Maryland, and Massachusetts.
Tuesday, October 25, 2011
Frozen Egg Products Recalled due to Salmonella
American Egg Products
Recalls Frozen Egg Product Because Of Possible Health Risk
Contact:
Consumer:
Jim Hull
(912) 449-5700
Consumer:
Jim Hull
(912) 449-5700
FOR IMMEDIATE RELEASE - October 24, 2011 -American Egg Products of Blackshear, Georgia, is recalling five pound cartons of frozen egg product, Lot #272-1, because they may be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonellaoften experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection withSalmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.
The recalled egg product was distributed to Georgia and Florida and sold to three distributors and/or further food manufacturers.
The product, American Egg Products Frozen Egg Product, comes in five pound paper cartons. Lot # 272-1 is printed across the side of the master case and is also embossed on the gable of each individual carton inside the case with the plant number as 272 1 P 1105.
No illnesses have been reported to date in connection with this product.
The recall was initiated as a result of a routine sampling by a private laboratory which revealed that the finished product containedSalmonella. The company has ceased distribution of the above referenced product. Investigation by the FDA and the company is ongoing to identify the source of the problem.
Consumers who have purchased this product, American Egg Products Frozen Egg Product, Lot # 272-1, are urged to return them to the place of purchase for a full refund. Consumers with questions may contact the company at 912-449-5700 Monday through Friday, between 8:00 a.m. and 5:00 p.m. Eastern time.
The recalled egg product was distributed to Georgia and Florida and sold to three distributors and/or further food manufacturers.
The product, American Egg Products Frozen Egg Product, comes in five pound paper cartons. Lot # 272-1 is printed across the side of the master case and is also embossed on the gable of each individual carton inside the case with the plant number as 272 1 P 1105.
No illnesses have been reported to date in connection with this product.
The recall was initiated as a result of a routine sampling by a private laboratory which revealed that the finished product containedSalmonella. The company has ceased distribution of the above referenced product. Investigation by the FDA and the company is ongoing to identify the source of the problem.
Consumers who have purchased this product, American Egg Products Frozen Egg Product, Lot # 272-1, are urged to return them to the place of purchase for a full refund. Consumers with questions may contact the company at 912-449-5700 Monday through Friday, between 8:00 a.m. and 5:00 p.m. Eastern time.
Monday, October 24, 2011
Chantix ( varenicline ): Risk of psychiatric problems!
FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of neuropsychiatric adverse events
Safety Announcement
Additional Information for Patients
Additional Information for Healthcare Professionals
Data Summary
References
[10-24-2011] The U.S. Food and Drug Administration (FDA) has reviewed the results from two FDA-sponsored epidemiological studies that evaluated the risk of neuropsychiatric adverse events associated with the smoking cessation drug Chantix (varenicline).
Facts about Chantix (varenicline) |
|
Neither study found a difference in risk of neuropsychiatric hospitalizations between Chantix and nicotine replacement therapy (NRT; e.g., NicoDerm patches). However, both studies had a number of study design limitations, including only assessing neuropsychiatric events that resulted in hospitalization, and not having a large enough sample size to detect rare adverse events (seeData Summary below for more information). Although these two studies did not suggest an increased risk of neuropsychiatric events that result in hospitalization, they do not rule out an increased risk of other neuropsychiatric events with Chantix.
Healthcare professionals and patients should continue to follow the recommendations in the physician label and the patient Medication Guide, and to monitor for neuropsychiatric symptoms when prescribing or using Chantix. Based on FDA’s assessment of currently available data, the Agency continues to believe that the drug’s benefits outweigh the risks and the current warnings in the Chantix drug label are appropriate.
The risk of serious neuropsychiatric events with Chantix is currently highlighted in the Boxed Warning and Warnings and Precautions section of the physician label and in the patient Medication Guide. Such events can include changes in behavior, hostility, agitation, depressed mood, and suicidal thoughts or actions. These warnings were based on postmarketing reports describing changes in mood and behavior during and after Chantix use (see 2008 Public Health Advisory and 2009 Public Health Advisory).
FDA is continuing to evaluate the risk of neuropsychiatric events with Chantix. The drug manufacturer is conducting a large safety clinical trial of Chantix to assess neuropsychiatric adverse events, and results from this study are expected in 2017.
- Some patients have experienced changes in behavior, hostility, agitation, depressed mood, and suicidal thoughts or actions while using Chantix to help them quit smoking. Some patients had these symptoms soon after they began taking Chantix, and others developed them after several weeks of treatment, or after stopping Chantix.
- Before taking Chantix, patients should inform their healthcare professional if they have ever had depression or other mental health problems.
- If a patient develops agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for them, or if a patient develops suicidal ideation or behavior, they should immediately discontinue Chantix and report these symptoms to their healthcare professional.
- Patients should read the Medication Guide that they get along with their Chantix prescription. It explains the risks associated with the use of Chantix.
- Patients should report serious side effects from the use of Chantix to the FDA MedWatch program, using the information in the "Contact Us" box at the bottom of this page.
- Healthcare professionals should continue to follow the recommendations in the drug label when prescribing Chantix.
- Serious neuropsychiatric adverse events, including, but not limited to, depression, suicidal ideation, suicide attempt, and completed suicide, have been reported in patients taking Chantix.
- Healthcare professionals should ask patients about any history of psychiatric illness, especially depression, prior to initiating treatment with Chantix.
- Healthcare professionals should advise patients and caregivers that the patient should immediately stop taking Chantix and contact a healthcare professional if agitation, hostility, depressed mood, or changes in behavior or thinking that are not typical for the patient are observed, or if the patient develops suicidal ideation or suicidal behavior while taking or shortly after discontinuing Chantix.
- Healthcare professionals should encourage patients to read the Medication Guide they receive along with their Chantix prescription.
- Healthcare professionals should report adverse events involving Chantix to the FDA MedWatch program, using the information in the "Contact Us" box at the bottom of this page
FDA sponsored two observational studies of neuropsychiatric adverse events with Chantix. One was conducted by the Department of Veterans Affairs’ (VA) Center for Medication Safety (VAMedSAFE), and the other by the Department of Defense’s (DoD) U.S. Army Medical Command’s Pharmacovigilance Center (PVC; hereafter referred to as the “DoD study”).
The VA study was a retrospective cohort study to evaluate the incidence of mental health hospitalizations among veterans using Chantix or nicotine replacement therapy (NRT). Patients starting Chantix or NRT between May 1, 2006 and September 30, 2007, but with no Chantix or NRT use in the previous year, were selected and matched in a 1:1 ratio by use of propensity scores (reflecting demographic characteristics, comorbidities, and psychiatric history). Propensity score matching is a method of balancing patient characteristics between the treatment groups being compared. The study’s main outcome was psychiatric hospitalization, with a coded primary discharge diagnosis for one of a number of psychiatric conditions, including drug-induced mental disorders, schizophrenic disorders, other psychotic disorders, depression, suicide attempts, and other mood disorders. Because the spontaneous adverse event reports for Chantix suggested a relatively short time to onset for psychiatric reactions, psychiatric hospitalizations for selected psychiatric diagnoses were assessed for 30 days after a prescription fill for Chantix or NRT.
The VA study population included 14,131 Chantix users and an equal number of NRT users. Among these patients, there were 16 psychiatric hospitalizations in Chantix-treated patients, and 21 in NRT patients. A Cox proportional hazards analysis showed no statistically significant difference in the risk of psychiatric hospitalization for Chantix users compared to NRT users (hazard ratio [HR] for Chantix/NRT = 0.76; 95% confidence interval [CI] 0.40-1.46). A complementary analysis in a prevalent user cohort of patients who had used NRT in the past before initiating Chantix or refilling an NRT prescription also showed no statistically significant difference in psychiatric hospitalizations between the two treatment groups. Also, the results using time periods longer than 30 days after a prescription fill were similar.
The DoD study was also a retrospective cohort study comparing the acute (30-day) rates of hospitalizations for neuropsychiatric adverse events among new users of Chantix (n=19,933) and NRT patch (n=15,867) who started therapy from August 1, 2006 to August 31, 2007 in the Military Health System. Patients were drawn from active duty military personnel, military retirees, and the dependents of either. Chantix users were matched using propensity scores to NRT users, with subgrouping by concomitant use of the prescription smoking cessation drug bupropion. After propensity score matching, there were 11,978 Chantix users and an equal number of NRT users in the study sample. The main outcome was a primary hospital discharge diagnosis for a neuropsychiatric condition. The following neuropsychiatric diagnoses were identified using ICD-9 codes: drug-induced mental disorders, transient mental disorders, schizophrenia, episodic and mood disorders, delusional disorders, other nonorganic psychoses, anxiety disorders, personality disorders, posttraumatic stress disorder (PTSD), depressive disorders, and suicide attempt.
In the DoD study’s propensity score matched samples, there were 18 psychiatric hospitalizations among Chantix users and 16 among NRT users. A Cox proportional hazard analysis did not show a statistically significant difference (HR for Chantix/NRT = 1.13; 95% CI 0.57-2.21). There was also no significant difference in psychiatric hospitalizations for Chantix users compared to NRT users when patients with concomitant bupropion use were excluded (HR = 0.91; 95% CI 0.39-2.14). Most (43) of the 55 neuropsychiatric hospitalizations (18 of the 23 Chantix events and 25 of the 32 NRT events) occurred in patients with a neuropsychiatric diagnosis in the year preceding the Chantix/NRT prescription fill, although such patients were a minority of the cohorts. Among patients with a neuropsychiatric diagnosis in the preceding year, 0.7% of Chantix users and 1.4% of NRT users were hospitalized for psychiatric care.
A strength of both studies was the inclusion of patients with pre-existing psychiatric disorders, since these patients were typically excluded from the clinical trials conducted with Chantix before it was approved (i.e., in premarketing trials).
Although neither study found a measurable increase in psychiatric hospitalizations with Chantix versus NRT, these results should be interpreted with the limitations of both studies in mind. The sample sizes in both studies were too small to assess rare, idiosyncratic events. Focusing on psychiatric hospitalizations is a useful approach for assessing the risk of serious neuropsychiatric adverse events, but it does not allow an assessment of less severe neuropsychiatric events that did not result in a psychiatric hospitalization (in the periods studied). Although the studies did not find a difference in psychiatric hospitalization risk between Chantix and NRT, they do not exclude the possibility that both treatments carry a similar risk. In addition, the VA study did not include PTSD as a reason for psychiatric hospitalization; one published report suggested that patients with PTSD may be more susceptible to the neuropsychiatric adverse effects of Chantix.3 Also, the DoD study only assessed a 30-day risk period following the fill date of the first qualifying prescription for Chantix or NRT and did not evaluate the rate of neuropsychiatric hospitalizations occurring over a longer duration following a Chantix prescription fill.
Overall, FDA has determined that the current warnings in the Chantix drug label, based on postmarketing surveillance reports, remain appropriate.
FDA is continuing to evaluate the risk of neuropsychiatric adverse events with Chantix. The manufacturer of Chantix, Pfizer, is conducting a large safety clinical trial of Chantix to assess neuropsychiatric adverse events as outcomes. Results from this trial are expected in 2017.
- MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US). Drug & Supplements Monograph: Varenicline. Available from:http://www.nlm.nih.gov/medlineplus/druginfo/meds/a606024.html. Accessed September 6, 2011.
- SDI, Vector One®: National (VONA) and Total Patient Tracker (TPT). May 2006-July 2011. Data extracted September 2011.
- Campbell AR, Anderson KD. Mental health stability in veterans with posttraumatic stress disorder receiving varenicline. Am J Health Syst Pharm. 2010;67:1832-7.
Saturday, October 15, 2011
Recalled: Pork Products Produced, Not Inspected!
| |||||
| |||||
|
Friday, October 14, 2011
Iceberg Lettuce, Brewers Yeast, Chicken & Steak Fajitas, Ground Tuna Recalled!
NOW Foods Issues Voluntary Recall of Brewer’s Yeast Tablets
fda.gov - Recall -- Firm Press Release FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties....Osamu Corporation Recalls Frozen Ground Tuna
fda.gov - Recall -- Firm Press Release FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested partie...Oklahoma Firm Recalls Center Cut Steaks Due to Misbranding and Undeclared Allergen
fsis.usda.gov - Colorado Firm Recalls Frozen Chicken and Steak Fajita Products Due to Misbranding Recall Release CLASS II RECALL FSIS-RC-82-2011 HEALTH RISK: LOW Congressional and Public Affairs (202) 720-9113 Ati...Media Statement on Voluntarily Recall of Giant Eagle Farmer's Market Shredded Iceberg Lettuce
da.gov - Recall -- Firm Press Release FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested partie..Wednesday, October 12, 2011
Botulism Risk! Uneviscerated Fish - Salted, Smoked & Split Herring
CFE International Fish Exporters Issues Alert on Uneviscerated Salted, Smoked, Split Herring
Lot Code: 1171, Plant Registration #2406
Contact:
Consumer:
James Scannell/Jeffrey Long
617-924-8300
Consumer:
James Scannell/Jeffrey Long
617-924-8300
FOR IMMEDIATE RELEASE - October 11, 2011 - CFE International, Canadian Fish Exporters, Inc. Auburndale, MA is recalling Salted, Smoked, Split Herring, , Lot Number: 1171, Plant Code: 2406 Producer: Leslie Leger & Sons, Ltd. Cap Pele, NB, Canada. A routine sample collected at a retail store by New York State Department of Agriculture and Markets found the product to be uneviscerated. Clostridium botulinum spores are more likely to be concentrated in the viscera than any other portion of the fish.
Botulinum spores can cause Botulism, a serious and potentially fatal food-borne illness. Botulism can cause the following symptoms: general weakness, dizziness, double-vision and trouble with speaking or swallowing. Difficulty in breathing, weakness of other muscles, abdominal distension and constipation may also be common symptoms. People experiencing these problems should seek immediate medical attention.
The product was distributed in 18 lb wooden boxes (40-60 count) thru distributors in: CT, FL, MA, MD, NJ, NY, PR, VA and packaged by retail stores in various weight range from ½ lb to 1.5 lb.
No illnesses have been reported to date.
Consumers are cautioned not to use this product, even if it does not look or smell spoiled, and it should be returned to the place of purchase. Consumers with any questions can contact: James Scannell/Jeffrey Long, CFE International Canadian Fish Exporters, Inc. 134 Rumford Avenue, Suite 202, Auburndale, MA 02466-1377 or by telephone 617-924-8300 between 9am -5 pm Monday through Friday.
Botulinum spores can cause Botulism, a serious and potentially fatal food-borne illness. Botulism can cause the following symptoms: general weakness, dizziness, double-vision and trouble with speaking or swallowing. Difficulty in breathing, weakness of other muscles, abdominal distension and constipation may also be common symptoms. People experiencing these problems should seek immediate medical attention.
The product was distributed in 18 lb wooden boxes (40-60 count) thru distributors in: CT, FL, MA, MD, NJ, NY, PR, VA and packaged by retail stores in various weight range from ½ lb to 1.5 lb.
No illnesses have been reported to date.
Consumers are cautioned not to use this product, even if it does not look or smell spoiled, and it should be returned to the place of purchase. Consumers with any questions can contact: James Scannell/Jeffrey Long, CFE International Canadian Fish Exporters, Inc. 134 Rumford Avenue, Suite 202, Auburndale, MA 02466-1377 or by telephone 617-924-8300 between 9am -5 pm Monday through Friday.
Tuesday, October 11, 2011
Commercial Meat Co. Recalls Ground Beef for E. Coli - Affects California, Nevada
| |||||||||||||||
| |||||||||||||||
| |||||||||||||||
Friday, October 7, 2011
Fresh Cut Cantaloupe ( by Fruit Fresh Up ) & Cut Mixed Fruit Recalled -- Again!
Fruit Fresh Up, Inc. Recalls Fresh Cut Cantaloupe and Cut Mixed Fruit
Containing Cantaloupe Distributed in New York State Because of
Possible Health Risk
Contact:
Consumer:
Company:
716-684-4300
Consumer:
Company:
716-684-4300
FOR IMMEDIATE RELEASE - October 6, 2011 - Fruit Fresh Up, Inc. of Depew, New York is recalling approximately 4,800 individual packages of FRESH CUT CANTALOUPE AND CUT MIXED FRUIT CONTAINING CANTALOUPE because they have the potential to be contaminated withlisteria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, listeria infection can cause miscarriages and stillbirths among pregnant women. Fruit Fresh Up, Inc. was not advised of the possible contamination of the cantaloupe it acquired from an independent wholesale vendor until last Thursday, September 27th.
The recalled FRESH CUT CANTALOUPE AND CUT MIXED FRUIT CONTAINING CANTALOUPE was distributed in Buffalo, New York and surrounding areas in retail stores and through catering orders.
The fresh cut fruit subject to this recall was sold between August 31, 2011 and September 11, 2011, and consisted of the following products: Cantaloupe Chunks, Cantaloupe Slices, Gourmet Fruit Salad, Small Fruit Salad, Small and Large Fruit Salad with Pineapple, Fruit Salad with Kiwi, and Fruit Trays. The packaging in which these products were packed has best-if-used-by dates ranging from September 4th through September 11th. No illnesses have been reported to date in connection with the cantaloupe processed by Fruit Fresh Up, Inc. Before cutting whole melons for packaging, Fruit Fresh Up, Inc. uses stringent procedures to minimize the risk of contamination. The rind of the whole cantaloupe is thoroughly washed with a sanitizing solution before cutting, and after the seeds are removed, the flesh is washed with this same solution before it is cut or sliced. Despite these procedures, which greatly minimize the risk of contamination, Fruit Fresh Up, Inc. is recalling these products out of an abundance of caution.
The Fruit Fresh Up, Inc. recall is part of a larger recall involving cantaloupe traced to Rocky Ford cantaloupes produced by Jensen Farms in Holly, Colorado. The Food and Drug Administration confirmed that listeria was found in samples taken from a Denver area store and the Jensen Farms packing facility. The melons were shipped to at least 17 different states across the U.S. between July 29th and September 10th. As of Wednesday there were a total of 96 illnesses, including 18 deaths, related to the contaminated cantaloupe sold by Jensen Farms. Jensen Farms earlier issued a voluntary nationwide recall of its cantaloupes after news of the multi-state outbreak. Jenson Farms has ceased production and distribution of the product while the FDA and the company continue their investigations as to what caused the problem.
Consumers having the recalled Fruit Fresh Up, Inc. product in their possession should return it to the place of purchase for a full refund or destroy it. Fruit Fresh Up, Inc. is located at 2928 Walden Avenue, New York 14043. Consumers with questions may contact the company at (716) 684-4300, Monday thru Friday, 8:00 am to 5:00 pm.
Thursday, October 6, 2011
Kraft Recalls Velveeta Shells & Cheese due to Wire Bristle Fragments
Kraft Foods Voluntarily Recalls Three Varieties of Velveeta Shells & Cheese Microwaveable Cups
With Limited “Best When Used By” Dates
Contact:
Consumer:
1-800-308-1841
Media:
847-646-4538
FOR IMMEDIATE RELEASE - Northfield, IL., September 30 2011 - Kraft Foods Global, Inc. is voluntarily recalling three varieties of Velveeta Shells & Cheese Single Serve Microwaveable Cups with limited “best when used by” dates as a precaution due to the possible presence of small, thin wire bristle pieces.
The following products are being recalled:
The following products are being recalled:
| Name of Product | Size | Best When Used By Dates | UPC |
|---|---|---|---|
| Velveeta Shells & Cheese Original Microwaveable Cups Velveeta Shells & Cheese Original Four Pack Microwaveable Cups | 2.39 oz. cup 4 x 2.39 oz. cup | 16 MAY 2012 24 APR 2012 to 16 MAY 2012 | 2100002322 2100002339 |
| Velveeta Shells & Cheese Made with 2% Milk Microwaveable Cups Velveeta Shells & Cheese Made with 2% Milk Four Pack Microwaveable Cups | 2.19 oz cup 4 x 2.19 oz cup | 25 MAR 2012 to 30 MAR 2012 29 MAR 2012 to 12 APR 2012 | 2100002323 2100002946 |
| Velveeta Rotini & Cheese Broccoli Microwaveable Cups | 2.44 oz cup | 29 APR 2012 to 14 MAY 2012 | 2100002318 |
No other “best when used by” dates of Velveeta Shells & Cheese Single Serve Microwaveable Cups or any other Kraft Foods products are being recalled.
There have been no reports of consumer injuries or complaints. Kraft Foods is issuing this voluntary recall out of an abundance of caution.
Approximately 137,000 cases of the affected products were shipped to customers across the United States. The affected products were not distributed in Canada.
Consumers who purchased affected “best when used by” dates of these products should not eat them. They should return them to the store of purchase for an exchange or full refund. Consumers also can contact Kraft Foods Consumer Relations Monday through Friday at 1-800-308-1841.
The affected products were manufactured in Champaign, IL and Lakeville, MN.
Tuesday, October 4, 2011
Salmonella found in Human & Animal Soy Flour
Thumb Oilseed Recalls Soy Flour (Utilized To Manufacture Human and Animal Food) Due To Salmonella Contamination
Contact:
Consumer:
Thumb Oilseed Producer’s Cooperative
(989) 658-2344
(866) 658-2344
Consumer:
Thumb Oilseed Producer’s Cooperative
(989) 658-2344
(866) 658-2344
FOR IMMEDIATE RELEASE - October 4, 2011 - Thumb Oilseed Producer’s Cooperative of Ubly, Michigan is recalling 2623, 40 lb. bags and 360, 1500 lb. totes of soybean flour; in addition to 924, .08 ton loads of bulk soy meal because they may be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Salmonella can affect animals eating the product and there is risk to humans from handling contaminated products. Especially if they have not thoroughly washed their hands after having contact with the product or any surfaces exposed to these products. Healthy persons infected with Salmonella often experience fever, diarrhea, nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe or chronic illnesses.
Animals with salmonella infections may be lethargic and have diarrhea or bloody diarrhea, fever, and/or vomiting. Some animals will have only decreased appetite, fever and abdominal pain. Infected but otherwise healthy animals can be carriers and infect other animals or humans. If your animal has consumed the recalled product and has these symptoms, please contact your veterinarian.
The soy flour was distributed in 40 lb. paper bags under the names:
Nex Soy (Lot numbers TF112310 thru TF033011) and
Soy Beginnings (Product Code 285100-NFB; Lot numbers TF112310 thru TF033011).
Animals with salmonella infections may be lethargic and have diarrhea or bloody diarrhea, fever, and/or vomiting. Some animals will have only decreased appetite, fever and abdominal pain. Infected but otherwise healthy animals can be carriers and infect other animals or humans. If your animal has consumed the recalled product and has these symptoms, please contact your veterinarian.
The soy flour was distributed in 40 lb. paper bags under the names:
Nex Soy (Lot numbers TF112310 thru TF033011) and
Soy Beginnings (Product Code 285100-NFB; Lot numbers TF112310 thru TF033011).
The soy flour was also distributed in 1500 lb. polyurethane totes under the name
Soy Beginnings (Product Code 285100-NFT, Lot numbers TF112310 thru TF082311).
Soy Beginnings (Product Code 285100-NFT, Lot numbers TF112310 thru TF082311).
The soy meal was distributed as .08 ton loads after custom processing with Lot numbers O011711 thru O081711.
The recalled soybean flour and meal was distributed to a limited group of wholesale customers located in Illinois, Vermont, Minnesota, Pennsylvania, Wisconsin, New Hampshire and Canada. The shipments occurred in November 2010 thru September 2011. Thumb Oilseed is contacting these customers and taking necessary steps to protect consumer health.
No illnesses have been reported to date. The recall resulted from routine sampling conducted by the company and US Food and Drug Administration (FDA) which revealed the bacteria in finished product and the manufacturing environment. Thumb Oilseed is cooperating with the FDA in investigating the situation.
This recall does not involve soy oil products produced by Thumb Oilseed.
Consumers who have purchased 40 lb. bags of Nex Soy (Lot numbers TF112310 thru TF033011) and Soy Beginnings (Product Code 285100-NFB, Lot numbers TF112310 and TF033011); 1500 lb. totes of Soy Beginnings (Product Code 285100-NFT, Lot numbers TF112310 and TF092311); and bulk meal with the Lot numbers O011711 thru O081711 are urged to return them to Thumb Oilseed Producers Cooperative for a credit or a refund. Consumers with questions may contact the company at 989-658-2344 between 9:00 am. and 4:00 pm. EST Monday-Friday.
The recalled soybean flour and meal was distributed to a limited group of wholesale customers located in Illinois, Vermont, Minnesota, Pennsylvania, Wisconsin, New Hampshire and Canada. The shipments occurred in November 2010 thru September 2011. Thumb Oilseed is contacting these customers and taking necessary steps to protect consumer health.
No illnesses have been reported to date. The recall resulted from routine sampling conducted by the company and US Food and Drug Administration (FDA) which revealed the bacteria in finished product and the manufacturing environment. Thumb Oilseed is cooperating with the FDA in investigating the situation.
This recall does not involve soy oil products produced by Thumb Oilseed.
Consumers who have purchased 40 lb. bags of Nex Soy (Lot numbers TF112310 thru TF033011) and Soy Beginnings (Product Code 285100-NFB, Lot numbers TF112310 and TF033011); 1500 lb. totes of Soy Beginnings (Product Code 285100-NFT, Lot numbers TF112310 and TF092311); and bulk meal with the Lot numbers O011711 thru O081711 are urged to return them to Thumb Oilseed Producers Cooperative for a credit or a refund. Consumers with questions may contact the company at 989-658-2344 between 9:00 am. and 4:00 pm. EST Monday-Friday.
Sunday, October 2, 2011
Thornton’s Quick Café’s Chef Salad Recalled for Salmonella
 |
 |
Congressional and Public Affairs (202) 720-9113 Bill Bagley WASHINGTON, October 1, 2011 - Greencore USA, Inc., a Cincinnati, Ohio, establishment, is recalling approximately 57 pounds of salad products containing meat and poultry, because the grape tomatoes used in these products may be contaminated with Salmonella, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today. The products subject to recall include: [View Labels (PDF Only)] Fresh Ground Turkey Chubs
Each package bears a label with the establishment number "P38518" inside the USDA mark of inspection and the enjoy-by date as noted above. The products subject to recall were produced on Sept. 26 and Sept. 28, 2011, and were distributed to retail stores in Ill., Ind., Ky., Ohio and Tenn. When available, trhe retail distribution list(s) will be posted on FSIS’ website at www.fsis.usda.gov/FSIS_Recalls/ Open_Federal_Cases/index.asp. The problem was discovered when Greencore USA, Inc. was notified by its grape tomato supplier, Pearson Foods, that a specific lot of grape tomatoes was being recalled due to potential Salmonella contamination. The Food and Drug Administration (FDA) announced the recall of grape tomatoes on Sept. 28, 2011. FSIS and the company are not aware of any illnesses in association with the recalled salad products.
Consumption of food contaminated with Salmonella can cause salmonellosis, one of the most common bacterial foodborne illnesses. Salmonella infections can be life-threatening, especially to those with weak immune systems, such as infants, the elderly, and persons with HIV infection or undergoing chemotherapy. The most common manifestations of salmonellosis are diarrhea, abdominal cramps, and fever within 6 to 72 hours. Additional symptoms may be chills, headache, nausea and vomiting that can last up to seven days. The outbreak strain of Salmonella Heidelberg is resistant to several commonly prescribed antibiotics; this antibiotic resistance may be associated with an increased risk of hospitalization or possible treatment failure in infected individuals. Members of the media with questions about the recall should contact the company’s CEO, Liam McClennon, at (978) 462-3663 ext. 313. Consumers with questions regarding the recall should contact the company’s Technical Manager, Mary Young, at (513) 377-0715. Consumers with food safety questions can "Ask Karen," the FSIS virtual representative available 24 hours a day at AskKaren.gov. The toll-free USDA Meat and Poultry Hotline 1-888-MPHotline (1-888-674-6854) is available in English and Spanish and can be reached from l0 a.m. to 4 p.m. (Eastern Time) Monday through Friday. Recorded food safety messages are available 24 hours a day. | ||||||||||||||
Subscribe to:
Posts (Atom)